Research & Development
Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.
Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.
Life Cycle Management
Products
Originator
Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Recordati
Molecule Name:
CARBAGLU®
Therapeautic Area:
Metabolic and other
Hyperammonaemia due to NAGS deficiency and to the main organic acidaemias
Phase/Status:
Registration
Development Details:
Regulatory Approval obtained in China in NAGS deficiency and organic acidaemias
Originator:
Recordati
Molecule Name:
CYSTADROPS®
Therapeautic Area:
Metabolic and other
Corneal cystine crystal deposits in patients with cystinosis
Phase/Status:
Late Stage
Development Details:
New Container Closure System
Originator:
Tolmar
Molecule Name:
ELIGARD®
Therapeautic Area:
SPC
Hormone-dependent prostate cancer
Phase/Status:
Late Stage
Development Details:
New device post-approval activities
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®*
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/Cushing's disease
Phase/Status:
Late Stage
Development Details:
Real World Evidence (LINC-7)
Originator:
Apeiron / Recordati
Molecule Name:
QARZIBA®*
Therapeautic Area:
Oncology
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
Phase/Status:
Late Stage
Development Details:
Relapsed/Refractory Induction
Originator:
Apeiron / Recordati
Molecule Name:
QARZIBA®
Therapeautic Area:
Oncology
Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma
Phase/Status:
Late Stage
Development Details:
Frontline Induction
Originator:
Novartis / Recordati
Molecule Name:
SIGNIFOR®*
Therapeautic Area:
Endocrinology
Post-Bariatric Hypoglycaemia
Phase/Status:
Proof of Concept
Development Details:
Phase II
Originator:
Recordati
Molecule Name:
SYLVANT®*
Therapeautic Area:
Oncology
IL-6 induced diseases
Phase/Status:
Proof of Concept
Development Details:
CRS/ICANs
Products
Originator
Molecule Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Recordati / AP-HP
Molecule Name:
REC 0545 / MAAPLIV*
Therapeautic Area:
Metabolic and other
Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis
Phase/Status:
Registration
Development Details:
Registration stage ongoing. Filing in EU done in 2023
Originator:
Recordati / MimeTech
Molecule Name:
REC 0559*
Therapeautic Area:
Metabolic and other
Neurotrophic Keratitis
Phase/Status:
Proof of Concept
Development Details:
Phase 2 in progress
Products
Originator
Molecule Name
Therapeutic area
Development Stage
Discover/
Preclinical
Proof of
Concept
Late
Stage
Registration
Post
Marketing
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/Cushing's disease
Phase/Status:
Post Marketing
Development Details:
Non-Interventional Study (LINC-6)
Originator:
Novartis / Recordati
Molecule Name:
ISTURISA®
Therapeautic Area:
Endocrinology
Endogenous Cushing's syndrome/ Cushing's disease
Phase/Status:
Post Marketing
Development Details:
Paediatric post-approval development plan
Originator:
Gedeon Richter
Molecule Name:
REAGLIA®
Therapeautic Area:
CNS
Schizophrenia
Phase/Status:
Post Marketing
Development Details:
Post marketing regulation
*= will result in new product indication
We are uniquely structured with multiple opportunities across our R&D team including CMC, preclinical, regulatory, patient safety, QA, clinical operations, clinical development, medical affairs. We are continuously growing, with a focus on developing new specialties, new treatments – and investing in medical innovations that bring a brighter future.
Interested in joining our team?
We foster an entrepreneurial environment where high-performing individuals are empowered to make a difference across our organisation.